바로가기메뉴

본문 바로가기 주메뉴 바로가기
 

logo

메뉴

Genes Associated with Short Stature: An Update

Abstract

Short stature is one of the most common reasons for referral to pediatric endocrinology clinics. In many children, no cause is identified, and they are classified as having idiopathic short stature (ISS). With recent advances in genetic testing, however, a growing number of these children are found to have monogenic defects. Linear growth is driven by chondrocyte proliferation, hypertrophy, and extracellular matrix production in the growth plate, and genetic variants that disrupt these processes impair growth. The affected mechanisms include endocrine signaling through the growth hormone (GH)–insulin-like growth factor I (IGF-I) axis; paracrine signaling and transcriptional regulation within the growth plate (SHOX, FGFR3, and NPR2); the cartilage extracellular matrix (ACAN); intracellular signaling (the RAS/MAPK pathway); fundamental cellular processes such as DNA replication and centrosome function; and genomic imprinting. Each mechanism is associated with a characteristic clinical pattern of birth size, body proportions, bone age, and biochemical findings. An accurate genetic diagnosis establishes the cause of growth failure, provides information on prognosis and associated risks, predicts the response to GH therapy, and enables genetic counseling. Mechanism-based therapies, such as C-type natriuretic peptide analogs for achondroplasia, are now entering clinical practice. In conclusion, the integration of clinical, biochemical, and genetic information according to the underlying cellular mechanisms is essential for the accurate diagnosis and management of children with short stature.

keywords
Body height, Growth plate, Growth disorders, Genetic testing

Received
2026-10-06
Revised
2026-10-20
Accepted
2026-10-26
Published
2026-10-31

logo